{"id":8829,"date":"2025-10-05T19:30:50","date_gmt":"2025-10-05T16:30:50","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8829"},"modified":"2025-10-05T19:30:50","modified_gmt":"2025-10-05T16:30:50","slug":"acc-scientific-statement-inflammation-and-cardiovascular-disease-consensus","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/acc-scientific-statement-inflammation-and-cardiovascular-disease-consensus\/","title":{"rendered":"ACC Scientific Statement: Inflammation and Cardiovascular Disease Consensus"},"content":{"rendered":"<div>ACC Scientific Statement: Inflammation and Cardiovascular Disease Consensus<\/div>\n<div><\/div>\n<div>(Source: ACC Medical News release, October 2, 2025, summarizing JACC publication from September 29, 2025)<\/div>\n<div><\/div>\n<div>Keynotes :<\/div>\n<div><span> 1. Inflammation is now a proven, treatable risk factor in CVD.<\/span><\/div>\n<div>\u2013 The ACC consensus confirms that inflammation plays a central role in coronary artery disease, heart failure, and atherosclerosis.<\/div>\n<div>\u2013 Evidence is no longer exploratory but clinically actionable.<\/div>\n<div><span> 2. Routine inflammation screening is strongly recommended.<\/span><\/div>\n<div>\u2013 The statement emphasizes high-sensitivity C-reactive protein (hsCRP) testing for all patients, in both primary and secondary prevention.<\/div>\n<div>\u2013 hsCRP \u22652 mg\/L indicates elevated inflammatory risk, even when LDL-C is controlled with statins.<\/div>\n<div>\u2013 hsCRP is as predictive of events as LDL-C, particularly in treated patients.<\/div>\n<div><span> 3. Lifestyle interventions remain first-line anti-inflammatory therapy.<\/span><\/div>\n<div>\u2013 150 minutes of weekly exercise, Mediterranean or DASH diet, and omega-3 (EPA\/DHA) intake are recommended.<\/div>\n<div>\u2013 These align with the 2025 ACC\/AHA Hypertension Guidelines.<\/div>\n<div><span> 4. Colchicine becomes first approved anti-inflammatory therapy for coronary disease.<\/span><\/div>\n<div>\u2013 Low-dose colchicine reduces cardiovascular events in chronic atherosclerosis when used in addition to statins.<\/div>\n<div>\u2013 It should not be started during acute ischemia and is contraindicated in significant liver or kidney disease.<\/div>\n<div><span> 5. Therapeutic recommendations in residual inflammation:<\/span><\/div>\n<div>\u2013 If hsCRP &gt;2 mg\/L despite statins, consider If hsCRP remains &gt;2 mg\/L despite optimal LDL-C therapy, ensure high-intensity statin use and consider adjunct anti-inflammatory therapy (e.g., low-dose colchicine).<\/div>\n<div>\u2013 Colchicine is now FDA-approved (2023) as the first on-label anti-inflammatory for chronic coronary inflammation who have persistent vascular inflammation (hsCRP &gt;2 mg\/L) despite optimal lipid-lowering therapy.<\/div>\n<div>\u2013 Ongoing trials are evaluating IL-6 inhibitors and novel bioactive lipid mediators for inflammation resolution.<\/div>\n<div><span> 6. Research gaps and future directions:<\/span><\/div>\n<div>\u2013 Some anti-inflammatory trials have failed in secondary prevention.<\/div>\n<div>\u2013 More evidence is needed to understand inflammation\u2019s interaction with other physiological systems (renal, metabolic, endothelial).<\/div>\n<div><span> 7. Key message:<\/span><\/div>\n<div>The ACC urges clinicians to incorporate hsCRP screening routinely and to consider anti-inflammatory strategies, including lifestyle optimization, colchicine, and emerging biologics, as part of comprehensive cardiovascular prevention.<\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2025.08.047\">https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2025.08.047<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ACC Scientific Statement: Inflammation and Cardiovascular Disease Consensus (Source: ACC Medical News release, October 2, 2025, summarizing JACC publication from September 29, 2025) Keynotes : 1. Inflammation is now a proven, treatable risk factor in CVD. \u2013 The ACC consensus confirms that inflammation plays a central role in coronary artery disease, heart failure, and atherosclerosis. [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8829","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8829"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8829\/revisions"}],"predecessor-version":[{"id":8830,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8829\/revisions\/8830"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}